Line 1: |
Line 1: |
| Also known as '''''FeLV | | Also known as '''''FeLV |
| + | [[Image:FeLV Electron Micrograph.jpg|thumb|right|175px|FeLV Electron Micrograph [http://phil.cdc.gov/phil/home.asp Public Health Image Library] Image #5610]] |
| | | |
| ==Introduction== | | ==Introduction== |
| + | [[Image:Kinetics of FeLV 2.jpg|thumb|right|200px|Kinetics of FeLV - Copyright Dr Brian Catchpole BVetMed PhD MRCVS]] |
| + | FeLV is an oncogenic mammalian type C retrovirus which causes neoplasia ([[Lymphoma|lymphoma]]), myelosuppression ([[Regenerative and Non-Regenerative Anaemias|anaemia]]) and immunosuppression (of [[Lymphocytes#T cells|T cells]]). Three different strains are currently recognised: |
| + | *FeLV-A -natural strain |
| + | *FeLV-B which formed through FeLV-A recombining with endogenous retroviral sequences in the feline genome. |
| + | *FeLV-C which formed from the spontaneous mutation of FeLV-A |
| + | |
| + | The virus replicates in the oropharyngeal lymphoid tissue causing a viraemia (the virus circulates in the bloodstream) which then spreads to the systemic lymphoid tissue. |
| | | |
| ==Pathogenesis== | | ==Pathogenesis== |
Line 9: |
Line 17: |
| *Salivary glands | | *Salivary glands |
| *Reproductive tract | | *Reproductive tract |
− | Most kittens but only 30% of adults become '''viremic''' for life without producing antibody. The condition progresses in various forms: | + | Most kittens but only 30% of adults become '''viraemic''' for life without producing antibody. The condition progresses in various forms: |
− | *20% of viremic cats die of tumors | + | *20% of viraemic cats die of tumors |
− | *30% of viremic cats die of FeLV-associated disease | + | *30% of viraemic cats die of FeLV-associated disease |
| *80% die within three years of exposure | | *80% die within three years of exposure |
− | 30% of adults exposed become '''latently infected''' and can become viremic when immunosuppressed. | + | 30% of adults exposed become '''latently infected''' and can become viraemic when immunosuppressed. |
| 40% of exposed adults remain healthy and develop Ab and CD8+ T cells after clearing the virus, without becoming reinfected or silent carriers. | | 40% of exposed adults remain healthy and develop Ab and CD8+ T cells after clearing the virus, without becoming reinfected or silent carriers. |
| | | |
Line 21: |
Line 29: |
| *'''Thymic lymphosarcoma''': T cell tumors, with only the thymus enlarged -this may result in dyspnoea and can be confirmed by radiography | | *'''Thymic lymphosarcoma''': T cell tumors, with only the thymus enlarged -this may result in dyspnoea and can be confirmed by radiography |
| *'''Alimentary lymphosarcoma''': B cell tumors of the Peyer's patches | | *'''Alimentary lymphosarcoma''': B cell tumors of the Peyer's patches |
| + | |
| + | |
| + | *Cutaneous horns on foot pads |
| + | *Epidermal and follicular epithelial hyperplasia, epidermal giant cells, dyskeratosis, necrosis, ulceration |
| | | |
| FeLV-associated disease: | | FeLV-associated disease: |
| *'''Immunodepression''' causing secondary disease | | *'''Immunodepression''' causing secondary disease |
− | *'''Reproductive failure''': FeLV crosses the placenta, causing fetal resorption or viremic kittens with thymic aplasia | + | *'''Reproductive failure''': FeLV crosses the placenta, causing fetal resorption or viraemic kittens with thymic aplasia |
| | | |
| ==Epidemiology== | | ==Epidemiology== |
Line 35: |
Line 47: |
| | | |
| There are 3 antigenic subgroups which are defined by the gp70 regulated viral response: | | There are 3 antigenic subgroups which are defined by the gp70 regulated viral response: |
− | *Group A is transmitted between cats and is monotypic: one vaccine covers all isolates. Infection with this viral subgroup leads to '''lymphosarcoma'''. | + | *Group A is transmitted between cats and is monotypic: one vaccine covers all isolates. Infection with this viral subgroup leads to '''[[Lymphoma|lymphosarcoma]]'''. |
− | *Group B is recombinant with transmissible FeLV-A; infection with viruses of this subgroup increases the chance of developing '''thymic tumors'''. | + | *Group B is recombinant with transmissible FeLV-A; infection with viruses of this subgroup increases the chance of developing '''[[Thymus Neoplasia|thymic tumours]]'''. |
− | *Group C is a mutant of subgroup A. Isolates are rare, and occur as A+C mixtures, leading to an increased chance of developing '''anemia'''. | + | *Group C is a mutant of subgroup A. Isolates are rare, and occur as A+C mixes, leading to an increased chance of developing '''[[Regenerative and Non-Regenerative Anaemias|anaemia]]'''. |
| | | |
| ==Diagnosis== | | ==Diagnosis== |
− | *FeLV should be suspect in any cat with '''recurrent bacterial infections''', '''anemia''' or '''weight loss'''. Diagnostic tests available for cinfirmation of disease sttus includes: | + | *FeLV should be suspect in any cat with '''recurrent bacterial infections''', '''anemia''' or '''weight loss'''. Diagnostic tests available for confirmation of disease status include: |
− | *'''ELISA''' for FeLV antigens (capsid protein p27 or envelope protein gp70) | + | *'''[[ELISA testing|ELISA]]''' for FeLV antigens (capsid protein p27 or envelope protein gp70) |
| *'''Immunochromatography''' is now preferred as ELISA testing can give false positives | | *'''Immunochromatography''' is now preferred as ELISA testing can give false positives |
| *'''Virus isolation''' from heparinised blood can be performed to confirm a positive diagnosis | | *'''Virus isolation''' from heparinised blood can be performed to confirm a positive diagnosis |
− | *Immunofluorescence | + | *[[Immunofluorescence]] |
| *PCR | | *PCR |
| *Rapid-Immuno-Migration | | *Rapid-Immuno-Migration |
− | *Western Blot | + | *[[Western blot|Western Blot]] |
| | | |
| ==Infection Control== | | ==Infection Control== |
Line 53: |
Line 65: |
| | | |
| ===Vaccination=== | | ===Vaccination=== |
− | Ideally, this should take place once antigen-negative status has been determined by laboratory testing. '''Leukogen''' is a subunit vaccine (using envelope protein gp70) produced in ''E. coli'' mixed with Quill-A and alhydrogel. Others include inactivated virus and canarypox recombinants, but all MUST include FeLV-A. | + | Ideally, this should take place once antigen-negative status has been determined by laboratory testing. 'Leukogen' is a subunit vaccine (using envelope protein gp70) produced in ''E. coli'' mixed with Quill-A and alhydrogel. Others include inactivated virus and canarypox recombinants, but all MUST include FeLV-A. |
− | | |
− | (FeLV)
| |
− | [[Image:FeLV Electron Micrograph.jpg|thumb|right|150px|FeLV Electron Micrograph [http://phil.cdc.gov/phil/home.asp Public Health Image Library] Image #5610]]
| |
− | [[Image:Kinetics of FeLV 2.jpg|thumb|right|150px|Kinetics of FeLV - Copyright Dr Brian Catchpole BVetMed PhD MRCVS]]
| |
− | *Oncogenic retrovirus
| |
− | *Causes neoplasia (lymphoma), myelosuppression (anaemia) and immunosuppression (of [[Lymphocytes#T cells|T cells]])
| |
− | *2 strains:
| |
− | **FeLV-A
| |
− | ***Natural strain
| |
− | **FeLV-B
| |
− | ***Formed through FeLV-A recombining with endogenous retroviral sequences in the feline genome
| |
− | ***Increases the risks of lymphoma
| |
− | **FeLV-C
| |
− | ***Formed from the spontaneous mutation of FeLV-A
| |
− | ***Is more myelosuppressive
| |
− | *Virus replicates in the oropharyngeal lymphoid tissue causing a viraemia (virus circulating in the bloodstream) which then spreads to the systemic lymphoid tissue
| |
− | *Shed in saliva
| |
− | *Passed by oronasal route, e.g. mutual grooming
| |
− | *Kittens between 6 weeks and 6 months are most susceptible
| |
− | *60% of cats will become immune to the disease and recover
| |
− | *Cats that are persistently viraemic will progress to develop FeLV-associated diseases
| |
− | *Some cats will become viraemic again if treated with corticosteroids or stressed if the infection lies dormant in the [[Bone Marrow - Anatomy & Physiology|bone marrow]]
| |
| | | |
| ==Treatment== | | ==Treatment== |
− | **Antibiotics for secondary infection
| + | Where treatment is undertaken, anti-retroviral therapy is indicated with antibiotics to control secondary infections. Prevention is a key element in the control and treatment of FeLV overall. |
− | **Anti-retroviral therapy
| |
− | *For vaccinations see [[Vaccines#Cat Vaccinations|here]]
| |
− | | |
| | | |
| + | {{Learning |
| + | |Vetstream = [https://www.vetstream.com/felis/Content/Disease/dis60141 Feline leukemia virus disease] |
| + | }} |
| | | |
| | | |
− | [[Category:Mammalian Type C retrovirus ]][[Category:Cat]][[Category:Secondary Immunodeficiency]] | + | [[Category:Mammalian Type C retrovirus ]][[Category:Cat Viruses]][[Category:Lymphoreticular and Haematopoietic Diseases - Cat]][[Category:Alimentary Diseases - Cat]][[Category:Secondary Immunodeficiency]] |
− | [[Category:To_Do_-_Clinical/Viruses]] | + | [[Category:Lymphoreticular and Haemopoietic Diseases]] |
− | [[Category:To Do - Blood]][[Category:To Do - Clinical]][[Category:Lymphoreticular and Haemopoietic Diseases]] | + | [[Category:Anaemia|6]] |
| + | [[Category:Integumentary System - Viral Infections]] |